methods: Maximum TWA was calculated by Modified Moving Average method in cases and age/sex-matched controls with EF <40% and VT ≥8 beats or SCD from MERLIN-TIMI 36 trial. All pts received standard therapy for NSTEACS plus ranolazine (N=109) or placebo (N=101) and had continuous ECG (cECG) recording for up to 7 days at admission. cECGs from 210 pts on Day 1 and 156 of these pts on Day 6 were interpretable for analysis after excluding pts with AF or ectopy.
results: Median max TWA on Day 1 was 35 μV (IQR 28,43). TWA ≥47 μV (established cutpoint) on Day 1 correlated with 1-year mortality, CV death, and VT ≥4 beats (Table) . On Day 6, median TWA was 36 μV (IQR 27, 46) . TWA ≥43 on Day 6 was associated with 1-year CV death (OR 4.50, 95%CI 1.4-14.3, p=0.011) in pts treated with placebo but not in pts treated with ranolazine (HR 0.30, 95% CI 0.04-2.6, p=0.27; p interaction 0.039). Overall, ranolazine did not reduce TWA between Days 1 and 6, although exploratory analyses suggest a reduction in TWA in pts with elevated baseline TWA ≥47μV.
conclusions: (1) In pts with NSTEACS, TWA ≥47 μV on Day 1 is associated with increased risk of total and CV mortality and NSVT at 1 year; (2) In pts with persistently elevated TWA, treatment with ranolazine may modify risk of mortality over 1 year, although further validation is needed. 
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